Drug recall · January 17, 2024
buPROPion Hydrochloride Extended-Release Tablets recall
Why: Presence of Foreign Tablets/Capsules
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03
- Lots / codes
Lot #: BPA123098A, Exp. Date 06/2025
- Quantity
- 47,976 bottles
- Company
- Rising Pharma Holding, Inc., East Brunswick, NJ
- Distribution
- Nationwide within the United States
- Initiated
- December 29, 2023 · Voluntary: Firm initiated
- Classified
- January 11, 2024
- Reported
- January 17, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.